SCHEMBL1870302

SCHEMBL1870302

CCOC(=O)C1=CC2(CCC1S(=O)(=O)Nc1ccccc1)OCCO2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 5/20 0.40
NPSR1 Q6W5P4 2/20 0.39
HPGD P15428 3/20 0.39
RECQL P46063 1/20 0.39
POLB P06746 1/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
MAPT P10636 2/20 0.38
GAA P10253 1/20 0.38
ICMT O60725 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1865497 0.90 TLR4 (0.46) TLR4NPSR1HPGDRECQLCA1
SCHEMBL1869694 0.90 TLR4 (0.47) TLR4NPSR1HPGDRECQLCA1
SCHEMBL1861053 0.88 TLR4 (0.43) TLR4HPGDRECQLMAPTGAA
SCHEMBL1866081 0.87 TLR4 (0.42) TLR4NPSR1HPGDRECQLPOLB
SCHEMBL1859103 0.86 TLR4 (0.42) TLR4NPSR1HPGDRECQLGAA
SCHEMBL1866089 0.86 KDM4E (0.42) TLR4HPGDMAPTGAASMN1; SMN2
SCHEMBL1867851 0.86 TLR4 (0.42) TLR4NPSR1HPGDRECQLCA1
SCHEMBL1862805 0.86 TLR4 (0.50) TLR4POLBMAPTGAASMN1; SMN2
SCHEMBL1859769 0.86 TLR4 (0.42) TLR4NPSR1HPGDRECQLGAA
SCHEMBL1866325 0.86 TLR4 (0.49) TLR4NPSR1MAPTSMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43858-E1 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-7935835-B2 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-7935835-B2 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
EP-1935879-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE CD40, LITAF, TNF TLR4 29/4885NPSR1 2438/4885HPGD 989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.